investor relations

corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM), metastatic non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). In the U.S., our therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway for use treating GBM and NSCLC, and under the Humanitarian Device Exemption (HDE) pathway for use treating MPM . We continue to explore the use of TTFields therapy for the treatment of GBM, NSCLC and pancreatic cancer.